Skip to main content
Article thumbnail
Location of Repository

A review of modafinil film-coated tablets for attention-deficit/hyperactivity disorder in children and adolescents

By Thomas Rugino

Abstract

Modafinil, a wakefulness-promoting agent unrelated to classical sympathomimetic stimulants, has been studied in a total of 933 children and adolescents as a treatment for attention-deficit/hyperactivity disorder (ADHD). Several studies, including three double-blind, placebo-controlled studies with intent-to-treat analyses, have demonstrated the efficacy of modafinil film-coated tablets in reducing symptoms of ADHD and associated problem behaviors in children and adolescents. Modafinil is generally well tolerated, with adverse events (such as insomnia, headache, loss of appetite, weight loss, and gastrointestinal discomfort) that are generally mild to moderate, rarely leading to medication discontinuation. To minimize treatment-emergent side effects, titration to the target dose of 355–425 mg once a day should take place over 2–3 weeks. Due to reports of skin rash (including one case of possible erythema multiforme/Stevens Johnson Syndrome during pivotal studies), additional studies have been requested to better evaluate the risks of developing severe cutaneous adverse reactions

Topics: Expert Opinion
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2654790
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2006). A comparison of once-daily and divided doses of modafi nil in children with attentiondefi cit/hyperactivity disorder:a randomized, double-blind, and placebocontrolled study.
    2. (2006). A randomized, double-blind, placebo-controlled study of modafi nil fi lm-coated tablets in children and adolescents with attention-defi cit/hyperactivity disorder.
    3. (2006). A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention defi cit hyperactivity disorder in children and adolescents. Health Technol Assess,
    4. (2002). Acute behavioral and physiological effects of modafi nil in drug abusers.
    5. (2000). An evaluation of the abuse potential of modafi nil using methylphenidate as a reference.
    6. (1999). Anterior cingulate cortex dysfunction in attention-defi cit/hyperactivity disorder revealed by fMRI and the Counting Stroop. Biol Psychiatry,
    7. (2000). CDC Growth Charts: United States. Adv Data,
    8. (1998). Cognitive neuroscience of attention defi cit hyperactivity disorder and hyperkinetic disorder.
    9. (1995). Comparative effects of modafi nil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs.
    10. (2000). Conners Parent Rating Scales – Revised: Technical Manual.
    11. (1991). Effect of modafinil and amphetamine on the ratcatecholinergic neuron activity.
    12. (2004). Effect of the wake-promoting agent modafi nil on sleep-promoting neurons from the ventrolateral preoptic nucleus:an in vitro pharmacologic study.
    13. (2001). Effects of modafi nil in children with attention-defi cit/hyperactivity disorder:an open-label study.
    14. (2005). Effi cacy and safety of modafi nil fi lm-coated tablets in children and adolescents with attentiondefi cit/hyperactivity disorder:results of a randomized, double-blind, placebo-controlled, fl exible-dose study.
    15. (2000). Evaluation of the abuse liability of modafi nil and other drugs for excessive daytime sleepiness associated with narcolepsy.
    16. (1996). Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafi nil.
    17. (1999). Functional magnetic resonance imaging neuroactivation studies in normal subjects and subjects with the narcoleptic syndrome. Actions of modafi nil.
    18. (2000). Hypothalamic arousal regions are activated during modafi nil-induced wakefulness.
    19. (1994). Lack of pre-synaptic dopaminergic involvement in modafi nil activity in anesthetized mice: in vivo voltammetry studies.
    20. (2006). Modafi nil (CEP- 1538) tablets Supplemental NDA 20-717/S-019 ADHD Indication:briefi ng document for Psychopharmacologic Drugs Advisory Committee Meeting.
    21. (1994). Modafi nil binds to the dopamine uptake carrier site with low affi nity.
    22. (2006). Modafi nil fi lm-coated tablets in children and adolescents with attention-defi cit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fi xed-dose study followed by abrupt discontinuation.
    23. (2003). Modafi nil in children with ADHD:a double blind, placebo controlled randomized study. Pediatr Neurol,
    24. (2005). Modafi nil modulates anterior cingulate function in chronic schizophrenia.
    25. (1997). Modafi nil:an antinarcoleptic drug with a different neurochemical profi le to d-amphetamine and dopamine uptake blockers. Biol Psychiatry,
    26. (2004). Modafi nil:preclinical, clinical, and post-marketing surveillance—a review of abuse liability issues. Ann Clin Psychiatry,
    27. (1999). Narcolepsy in orexin knockout mice:molecular genetics of sleep regulation.
    28. (2000). NIMH Diagnostic Interview Schedule for Children version IV (NIMH DISC-IV):description, differences from previous versions, and reliability of some common diagnoses.
    29. (1995). Non-amephtaminic mechanism of stimulant locomotor effect of modafi nil in mice.
    30. (1996). Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafi nil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat.
    31. (2004). Prescribing Information:Provigil (Modafi nil) Tablets PRO542.
    32. (2006). Presentation to the Pediatric Advisory Committee to the United States Food and Drug Administration;
    33. (2006). Psychiatric adverse events with drug treatment of ADHD.
    34. (1992). Role of catecholamines in the modafi nil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res,
    35. (1990). Social Skills Rating System Manual. Circle Pines: Minnesota:American Guidance Service.
    36. (1998). Statistical power analysis for the behavioral sciences (2nd ed).
    37. (2006). Stimulants:Therapeutic actions in ADHD. Neuropsychopharmacology, E-pub ahead of print.
    38. (2002). Study of the addictive potential of modafi nil in naive and cocaine-experienced rats.
    39. (2005). Treatment of attentiondefi cit/hyperactivity disorder:overview of the evidence. Pediatrics,

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.